Life
Roche Initiates Phase 3 Trial for Elevidys in Pursuit of European Approval
Roche is set to begin a Phase 3 trial for its Duchenne gene therapy, Elevidys, aiming for potential approval in Europe amidst ongoing controversy.
editorial-staff
1 min read
Updated about 3 hours ago
Summary
Roche has announced the launch of a Phase 3 clinical trial for Elevidys, a gene therapy aimed at treating Duchenne muscular dystrophy.
This move comes as the company seeks to secure approval for the therapy in Europe, where it has faced scrutiny.
The trial's outcome could significantly impact the future availability of Elevidys for patients in need.
Updates
- No subsequent updates recorded.